Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant mFOLFIRINOX With Peri-operative Hydroxychloroquine in Resectable Pancreatic Cancer
NCT04911816Phase 2Recruiting
- Sponsor
- West Virginia University
- Start
- Jul 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxychloroquine in pancreatic adenocarcinoma (PDAC), sponsored by West Virginia University. Primary endpoints: Maximum Tolerated Dose and Rate of grade IIb or better histopathological response up to 4 months. Started Jul 2021; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04911816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04911816.